Printer Friendly

TELOR OPHTHALMIC PHARMACEUTICALS, INC. ANNOUNCES THE APPOINTMENT OF SOPHANN IM, PH.D., TO MANAGER OF PHARMACEUTICAL DIVISION

 TELOR OPHTHALMIC PHARMACEUTICALS, INC. ANNOUNCES THE APPOINTMENT
 OF SOPHANN IM, PH.D., TO MANAGER OF PHARMACEUTICAL DIVISION
 WOBURN, Mass., Sept. 29 /PRNewswire/ -- Telor Ophthalmic Pharmaceuticals, Inc. today announced that Sophann Im, Ph.D., formerly of Bausch & Lomb Pharmaceutical Division and Alcon Laboratories, Inc., has joined the company as manager of pharmaceutical development.
 "Sophann has worked for pharmaceutical and ophthalmic companies for over 17 years, primarily overseeing the development of new medical products and evaluating the scientific merits of new technologies," said Stephen J. Riggi, Ph.D., president and chief executive officer of Telor. "Telor looks forward to his contributions in these areas as the firm grows and our products in development advance."
 Prior to joining Telor, Dr. Im served as director, pharmaceutical development for Bausch & Lomb Pharmaceutical Division. He also worked at Alcon Laboratories as manager, product development and senior scientist/group leader and at Boehringer Ingelheim Ltd. as senior scientist/group leader. He received his B.S. in pharmacy from the University of New Mexico, his M.S. in pharmacy from Ohio State University, his Industrial Pharmacy Diploma from Montpellier Institute of Industrial Pharmacy, and his Ph.D. in pharmaceutics from the University of Montpellier in Montpellier, France.
 Telor Ophthalmic Pharmaceuticals, Inc. is developing innovative products for the treatment of age-related eye diseases. The company's initial products in development are for controlling intraocular pressure following surgery and in glaucoma, and for other diseases of the eye. Telor began operations in 1989 and has its headquarters in Woburn, Mass.
 -0- 9/29/92
 /CONTACT: Stephen J. Riggi, Ph.D., president and CEO of Telor Ophthalmic Pharmaceuticals, 617-937-0393; or Lynne Brum of Feinstein Partners, 617-577-8110, for Telor Ophthalmic/ CO: Telor Ophthalmic Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU: PER


CH -- NE003 -- 4215 09/29/92 08:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1992
Words:297
Previous Article:HOWTEK AND 3M SIGN AGREEMENT FOR D4000 DRUM SCANNER; SCANNER TO BE OFFERED AS INPUT DEVICE FOR 3M SCOTCHPRINT ELECTRONIC GRAPHIC SYSTEM
Next Article:HOWARD JOHNSON UPGRADES FOR THE 90S WITH GATELODGE IMAGE ENHANCEMENT PROGRAM; OFFERS FINANCIAL INCENTIVES TO FRANCHISEES WHO RENOVATE
Topics:


Related Articles
FREDERICK H. GARBER JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC. AS VICE PRESIDENT OF MARKETING
WALTER P. RAHN II JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC.
WALTER P. RAHN II JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC.
TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS REGULATORY AFFAIRS GROUP; APPOINTS DIRECTOR, REGULATORY AFFAIRS AND COMPLIANCE OFFICER
PHYTERA, INC. ANNOUNCES KEY MANAGEMENT, SCIENTIFIC APPOINTMENTS
TELIOS APPOINTS FORMER ELI LILLY & COMPANY EXECUTIVE DONALD W. GRIMM AS CHIEF EXECUTIVE OFFICER
CLOSING COMPLETED, SANOFI NAMES MANAGEMENT TEAM FOR PHARMACEUTICAL DIVISION
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
MARSAM PHARMACEUTICALS INC. ANNOUNCES APPOINTMENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters